RxDoctor Payments Data

Nunzio Bottini

Rheumatology · Los Angeles, CANPI 1124303011

Payments from drug & device makers

$199,204in general payments, 2019–2025

Across 17 payments — averaging $11,718 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$186K
  • Merck$13K
  • Eli Lilly$28
  • Viiv Healthcare Company$18

What the payments were for

  • Consulting fees$11,37086%
  • Travel & lodging$1,44511%
  • Food & beverage$3893%

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
F. Hoffmann-la Roche AG2$186,000
Merck13$13,159
Eli Lilly1$28
Viiv Healthcare Company1$18

How this compares

$199,204 in reported general payments places this provider in the 85th percentile of 808 rheumatology providers in California.

See all rheumatology providers in California

Medicare billing

Part B allowed, 2024
$2,800
Medicare patients
12
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mycophenolate Mofetil12$15,451

Paid to pharmacies, not to this prescriber.

Other rheumatology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →